Is NRXP or NTHI more undervalued in 2026?

CirclFi compares NRX Pharmaceuticals, Inc. (NRXP) and NeOnc Technologies Holdings, In (NTHI) using 13 institutional-grade valuation models. NRXP has a Quality of Company score of 3.9/10 while NTHI scores 3.7/10.

Which is a better buy — NRXP or NTHI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NRXP and NTHI valuations compare?

NRXP at $4.44 and NTHI at $4.79 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NRXP vs NTHI Valuation Comparison 2026 — Intrinsic Value Analysis

NRXP

Biotechnology

NRX Pharmaceuticals, Inc.

Quality

3.9

out of 10

Value Trap

LOW

Price

$4.44

Last close

Models

10/13

Active

NTHI

Biotechnology

NeOnc Technologies Holdings, In

Quality

3.7

out of 10

Value Trap

—

Price

$4.79

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	NRXP Fair Value	NRXP Upside	NTHI Fair Value	NTHI Upside
Bayesian DCF	Intrinsic	$1.26	-71.6%	$0.70	-85.4%
Earnings Power Value	Intrinsic	$0.34	-89.0%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	—	—	$2.71	-50.2%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NRXP vs NTHI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NRXP vs NTHI — Which Stock Is More Undervalued?

NRXP scores higher with a 3.9/10 quality rating vs NTHI's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing NRX Pharmaceuticals, Inc. (NRXP) and NeOnc Technologies Holdings, In (NTHI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NRXP currently trades at $4.44 with a QOC of 3.9/10, while NTHI trades at $4.79 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).